The US FDA granted approval based on results from ARIEL3, a randomized clinical trial conducted with 561 eligible cancer patients.
Researchers hypothesize that ovarian cancer may be X-linked and associated genes may be passed from the paternal grandmother via the father's inherited genetic material.
An USPSTF updated recommendation statement for ovarian cancer screening recommends against screening for women who are asymptomatic and do not have high-risk hereditary cancer syndrome.
Researchers conducted a meta-analysis to examined possible links between antidepressant use and epithelial ovarian cancer, and links between duration and intensity of antidepressant use and risk for epithelial ovarian cancer.
Researchers sought to determine if a correlation was present between extended oral contraceptive use and a decreased risk of certain cancers.
Researchers explored the effectiveness of wearing frozen gloves and socks before and after treatment with PLD to prevent or manage hand-foot syndrome in patients with ovarian cancer.
Hyperthermic intraperitoneal chemotherapy with surgery increases survival for epithelial ovarian cancer patients
1. Patients with stage 3 epithelial ovarian cancer treated with hyperthermic intraperitoneal chemotherapy (HIPEC) in addition to cytoreductive surgery and neoadjuvant chemotherapy experienced increased overall and recurrence-free survival compared to those treated with surgery and chemotherapy alone. 2. No difference in grade 3 or 4 adverse side effects were observed between HIPEC and non-HIPEC treated 
1. BRCA1 promoter methylation in normal white blood cells (WBCs) was linked to risk for high-grade serous ovarian cancer (HGSOC). 2. BRCA1 methylation was detected in women of all ages, including newborns, suggesting that BRCA1 methylation happens at an embryonic stage. Evidence Rating Level: 3 (Average) Study Rundown: Females with BRCA1 mutations in their germline 
Results of a double-blind phase 2 study determined if adding oral pazopanib to intravenous paclitaxel improved outcomes for women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
Multimodal screening is more expensive, but reduces ovarian cancer mortality, researchers found.
Researchers have found 3 major predictors for survival: tumor infiltrating leukocytes (TIL), programmed death-ligand 1 (PD-L1) expression, and mutational burden.
Ovarian cancer risk is known to be increased by BRCA1 and BRCA2 gene mutations, but recent developments have led researchers to believe there are several genes involved in homologous recombination-mediated DNA damage.
Administering niraparib to patients with recurrent ovarian cancer after CR or PR to platinum-based chemotherapy may allow patients to continuously maintain QOL during treatment, reported researchers in presentation at ESMO 2017 Congress.
Survival rate were worse for lower volume hospitals with higher quality scores, versus higher volume hospitals.
Risk assessment study for carriers of the BRCA1/2 mutation identified the factors that influence their risk of developing breast cancer, ovarian cancer, or contralateral breast cancer.
A questionnaire added to intake forms at a breast cancer imaging center identified women with BRCA mutations who might otherwise have been missed.
Change in FACT-O TOI score from baseline to 12 months did not differ significantly between maintenance olaparib and placebo.
Rubraca (rucaparib) received accelerated approval by the U.S. Food and Drug Administration for the treatment of patients with previously treated BRCA-positive ovarian cancer.
Including a PI3-Kinase Inhibitor with an PARP Inhibitor Improves Tumor Shrinkage in Patients with Resistant Ovarian Cancer
Tumor shrinkage was seen in plantinum-resistant ovarian tumors when treated with a combination of a PARP inhibitor and an alpha-specific PI3-kinase inhibitor.
Quality of life was maintained in patients with ovarian cancer who received chemotherapy with concurrent cediranib then cediranib alone as maintenance therapy.
A team of international researchers identified 12 new genetic variants that increase a woman's risk of developing ovarian cancer.
A protocol of testing of CA125 levels quarterly with subsequent transvaginal ultrasound examination increased detection of early-stage ovarian cancer in women at high-risk for the disease.
There are 18 core priority symptoms that should be routinely assessed in patients with recurrent ovarian cancer to provide higher quality of care.
Nurse-guided and self-directed web-based symptom management interventions (WRITE Symptoms) improved symptom controllability among women with recurrent ovarian cancer.
Study finds that instituting a health system-wide quality metric, such as postoperative hospital readmission rate, may be inconsistent with long-term clinical outcomes goals.
A study that integrated genomic and clinical data identified 3 distinct clusters of patients with serous epithelial ovarian cancer who do not respond to chemotherapy.
An enhanced recovery program is more cost-effective than usual care in patients undergoing primary cytoreductive surgery for ovarian cancer.
Rucaparib was active with an acceptable safety profile in patients with relapsed, platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations.
Individuals with serious carcinoma of the ovary or peritoneum experienced improved progression-free survival after hormone maintenance therapy.
Rucaparib has been approved for the treatment of patients with advanced ovarian cancer who harbor a deleterious BRCA mutation.
The benefits of primary cytoreductive surgery relative to neoadjuvant chemotherapy remain uncertain; therefore, researchers performed a retrospective data analysis to compare overall survival of surgery with that of neoadjuvant chemotherapy in advanced-stage epithelial ovarian cancer.
NeoadjuvantcChemotherapy (NACT) use went up from 2003 to 2012; linked to shorter overall survival in stage IIIC but not stage IV disease.
Etoposide was found to damage ovarian tissue in the developing fetus in a study evaluating the effect of the drug on mouse ovarian tissue grown in vitro.
Rapid, robust, and affordable genetic testing for patients with ovarian cancer that allows a much larger portion of patients to benefit from personalized cancer management and their relatives to benefit from preventive strategies can be achieved.
Risk of ovarian cancer is higher in African American women with lower socioeconomic status, the opposite of trends seen in breast cancer.
A newly created tumor-specific fluorescent molecule combined with an imaging system guided surgeons to removing additional tumors not palpable or visible without fluorescence in patients with ovarian cancer.
Immunotherapy for advanced ovarian cancer more effectively treats tumors when administered immediately after chemotherapy. Sequential chemoimmunotherapy could improve disease control in stage IIIC/IV tubo-ovarian HGSC.
Chronic inactivity has been linked to greater risk for ovarian cancer.
The number of patients older than 75 years who do not undergo surgery is increasing, especially among those with stage III or IV ovarian cancer. Approximately 50% do not undergo surgery and 25% receive no treatment at all.
Overall risk of developing ovarian cancer may be higher for women with certain types of human leukocyte antigen (HLA), which could underlie differences in their response to immunotherapy.
Cell Changes in Fallopian Tubes of BRCA Mutation Carriers May Lead to Strategies for Preventing Ovarian Cancer
Recognition of early changes in the Fallopian tube cells of BRCA gene mutation carriers may be key to new strategies for preventing ovarian cancer that could also reduce the need for invasive surgery.
Disparities in cancer risk management among BRCA carriers across a diverse sample of young black, Hispanic, and non-Hispanic white breast cancer survivors underscores that "the benefit from genetic testing comes from acting on the test results," not just the testing itself, a study presented at the ASCO 2016 Annual Meeting concluded.
A new perspective on chemotherapy resistance in ovarian cancer may be a step toward overcoming that resistance. Fibroblasts block chemotherapy, leading to chemotherapy resistance; however, immune system T cells can reverse that resistance.
No Clinical Benefit to Expanding Gene Panel Beyond Ovarian and Breast Cancer Genes in High-risk Women
Expanding a panel of tested genes beyond the known breast and ovarian cancer-specific genes in patients with breast and ovarian cancer did not confer any clinical benefit.
Excess abdominal fat in overweight and obese women could interfere with detection of early symptoms of ovarian cancer, and this may contribute to the higher risk of death from ovarian cancer in African American women compared with white women.
Effect of Childbirth on Risk of Ovarian Cancer Diminishes With Age, But Effect of Oral Contraceptive Use Is Constant
Prior oral contraceptive use is associated with reduced risk for ovarian cancer among women of all ages; however, risk reductions associated with childbirth wane as women age
Women who are long-term survivors of high-grade serous carcinoma (HGSC) usually have platinum-sensitive disease.
Risk-reducing mastectomy (RRM) can increase life expectancy and be cost effective in women up to age 60 years with ovarian cancer as carriers of a BRCA mutation.
Women who received tamoxifen plus ovarian function suppression (OFS) reported worse endocrine symptoms and sexual functioning.
Hormone Replacement Therapy Improves Bone Mineral Loss After Salpingo-oophorectomy for Ovarian Cancer
In patients who undergo risk-reducing salpingo-oophorectomy, BMD screenings are underutilized in spite of the prevalence of bone mineral loss in this population. Hormone replacement therapy can address BMD loss in these women.
Progression-free and Overall Survival Better With Mutations Affecting DNA Repair Genes in Ovarian Cancer
Women with advanced ovarian cancer who had mutations affecting DNA repair genes had longer progression-free and overall survival than women without the mutations.
Current use of antihypertensive medication may be associated with a slightly increased risk for ovarian cancer.
Adding farletuzumab to carboplatin and a taxane failed to improve progression-free survival in patients with platinum-sensitive ovarian cancer.
[Journal of Gastrointestinal Oncology] This research examines the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of ovarian cancer.
Ovarian cancer isn't a single disease, but rather a number of different malignancies, and better understanding is needed to improve prevention and treatment according to a U.S. panel.
Paclitaxel administered with carboplatin on a weekly basis is not associated with improved progression-free survival.
Among 1915 patients with ovarian cancer, almost 1 in 5 had inherited mutations in genes associated with risk of ovarian cancer. Furthermore, a total of 11 genes are now suspected of causing hereditary ovarian cancer.
The researchers found that nearly one fifth of women with ovarian cancer carried mutations in genes that were associated with ovarian cancer risk beyond the BRCA1 and BRCA2 genes.
A recent study fine-tuned the popular Simple Rules ultrasound test for ovarian cancer.
An in-depth look at the issues associated with the care reveals a need to improve how clinicians can help these women sort through their options.
Combining a maximal debulking strategy and intraperitoneal chemotherapy could maximize the chance of achieving a cancer-free state, as explained in a recent clinical perspective piece.
Minimally invasive hysterectomy does not appear to compromise long-term survival compared with abdominal hysterectomy.
Ob-gyns report external examinations are important for cancer detection and lesion identification.
The National Comprehensive Cancer Network (NCCN) has published its NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines).
A study compared the effectiveness of volasertib versus chemotherapy for treatment of platinum-resistant or -refractory ovarian cancer.
Twins carry a significant excess familial risk for cancer overall and for specific types of cancer, including prostate, melanoma, breast, ovary, and uterus, according to a long-term follow-up study of twins in Nordic countries.
The longest survival time was observed for primary debulking surgery coupled with chemotherapy in an optimal timeframe.
Obesity potently increases the potential for metastasis of ovarian cancer. A large number of studies have shown that higher body mass index is associated with a greater risk for ovarian cancer with worse overall survival.
Tracking levels of the CA125 protein over time may help to reduce ovarian cancer deaths by as much as 20%.
Women who have ovarian cancer often develop ascites, a buildup of fluids in the abdomen. Researchers have found that ascites can be reduced with minimal side effects through inhibition of the colony-stimulating-factor-1 receptor (CSF1R).
The protein cytokeratin 5 (CK5), known to be a marker of poor prognosis in patients with breast cancer, also marks ovarian cancers likely to be resistant to the common chemotherapy cisplatin.
The more children a woman has or whether she has undergone tubal ligation lowers her risk of different types of ovarian cancer to different levels, according to new research presented at the 2015 NCRI Cancer Conference.
A healthy diet may reduce the risk for developing ovarian cancer in African American women.
Patients who develop ovarian cancer may have improved outcomes if they have prior oral contraceptive use.
Venlafaxine has a significant clinical activity against taxane-oxaliplatin-induced acute neurosensory toxicity in patients with cancer.
Survival for women with advanced ovarian cancer may be negatively impacted when chemotherapy is initiated more than 25 days after surgery.
Women with epithelial ovarian cancer, the most common type, can safely take hormone replacement therapy (HRT).
Researchers have made a significant advance in the use of photodynamic therapy to combat ovarian cancer in laboratory animals, using a combination of techniques that achieved complete cancer cell elimination with no regrowth of tumors.
Some drugs normally taken to treat heart ailments may also be beneficial for ovarian cancer.
Beta-blockers, particularly first-generation nonselective beta-blockers, improved overall survival among patients with epithelial ovarian cancer.
There is no significant quality of life advantage of cisplatin plus topotecan in treatment of women with newly diagnosed ovarian cancer.
RAD51C and RAD51D deleterious mutations have been linked to increased risk of epithelial ovarian cancer.
High-grade serous ovarian cancer often responds well to the chemotherapy drug carboplatin, but researchers are investigating why it frequently returns after treatment.
Multigene testing for hereditary breast and/or ovarian cancer that tests is more likely to inform clinical decision-making than testing for BRCA1/2 alone.
Predictors for long-term survival include younger age, early stage, low grade, non-serous histology
Despite survival benefits, only 41 percent of suitable candidates actually receive the therapy.
Survival rates for ovarian cancer are higher than predicted for most women.
Overweight or obese patients with ovarian cancer are typically given lower per-pound chemotherapy doses to reduce toxic side effects, which could impact their survival chances.
Researchers have found that spending more leisure time sitting was associated with an increased risk for developing cancer in women.
Researchers have found that the experimental drug fostamatinib, combined with the chemotherapy drug paclitaxel, may overcome ovarian cancer cells' resistance to paclitaxel.
The discovery of three genetic variants associated with mucinous ovarian carcinomas (MOCs) offers the first evidence of genetic susceptibility in this type of ovarian cancer.
Researchers have identified a molecule that may play a central role in chemotherapy resistance in patients with the most common ovarian cancer.
Women with advanced ovarian cancer have fewer side effects and tend to have a better quality of life if given chemotherapy before surgery.
A new screening method utilizing protein analysis can detect ovarian cancer in twice as many women as conventional strategies, according to the latest trial results.
miR-506 may play a role in chemotherapy resistance in patients with ovarian cancer.
Screening using risk of ovarian cancer algorithm linked to increased number of screen-detected iEOCs.
Women with ovarian cancer should be tested for BRCA1 and BRCA2 gene mutations, regardless of their family history.
Women diagnosed with ovarian cancer today are 50 percent less likely to die than they were in the 1970s.
A new screening tool can detect twice as many women with ovarian cancer as standard approaches.
An early stage trial for mesothelioma and pancreatic and ovarian cancers has explored utilizing a patient's own immune cells, genetically modified to target tumors.
Sign Up for Free e-newsletters
- Cancer Treatment and Research: What Lies Ahead in 2019
- Helping Patients Face the Challenge of Eating Healthy During Cancer Treatment
- Continuous Therapy May Be Beneficial in Patients With Newly Diagnosed Multiple Myeloma
- Regular Physical Activity — Even Initiated Postdiagnosis — Improves Survival for Cancer Patients
- Gastrointestinal Perforation Complicates Management of Mantle Cell Lymphoma
- Brain Exercise Program Eases Chemobrain in Breast Cancer Survivors
- Hormone Therapy for Breast Cancer (Fact Sheet)
- Counseling on the Dangers of Vaping
- Radical Prostatectomy vs Active Surveillance: Results of Nearly 3 Decades of Follow-up
- Potential of Fecal Microbiota Transplantation in Managing Immunotherapy-Associated Colitis
- Ixazomib Maintenance After ASCT Improves Progression-Free, Overall Survival in Multiple Myeloma
- Evolutionary Role of Chemotherapy in Advanced Nasopharyngeal Carcinoma: A Literature-based Network Meta-analysis
- Helping Patients Face the Challenge of Eating Healthy During Cancer Treatment
- Gastrointestinal Perforation Complicates Management of Mantle Cell Lymphoma
- Modernizing Eligibility Criteria Could Increase Access to, Participation in Clinical Trials
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|